Cancer-testis antigen expression and immunogenicity in AL amyloidosis

M. A. Rosenzweig; H. Landau; D. Seldin; C. Ohara; S. Girnius; N. Hanson; D. Frosina; C. Sedrak; M. Arcila; R. L. Comenzo; S. Giralt; S. Gnjatic; A. A. Jungbluth; G. Koehne

doi:10.1038/bcj.2012.32

Cancer-testis antigen expression and immunogenicity in AL amyloidosis

M. A. Rosenzweig, H. Landau, D. Seldin, C. Ohara, S. Girnius, N. Hanson, D. Frosina, C. Sedrak, M. Arcila, R. L. Comenzo, S. Giralt, S. Gnjatic, A. A. Jungbluth, G. Koehne

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Light-chain amyloidosis (AL) is a plasma cell dyscrasia closely related to multiple myeloma. In multiple myeloma, the cancer-testis antigens (CTAs) CT7 (MAGE-C1), CT10 (MAGE-C2) and MAGE-A CTAs are expressed in up to 80% of cases. In this study, we investigated the expression and immunogenicity of several CTAs in patients with AL amyloidosis in a total of 38 bone marrow specimens by employing standard immunohistochemistry techniques on paraffin-embedded archival tissues. Plasma samples from 35 patients (27 with matched bone marrow samples) were also analyzed by ELISA for sero reactivity to a group of full-length CTA proteins. CT7 was present in 25/38 (66%) while CT10 was demonstrated in 3/38 and GAGE in 1/38 AL amyloid cases. The expression pattern was mostly focal. There were no significant differences with regard to organ involvement, response to treatment, or prognosis in CTA positive compared to negative cases. None of the specimens showed spontaneous humoral immunity to CT7, but sero reactivity was observed in individual patients to other CTAs. This study identifies CT7 as the prevalent CTA in plasma cells of patients with AL amyloidosis. Further analyses determining the biology of CTAs in AL amyloidosis and their value as potential targets for immunotherapy are warranted.

Original language	English
Article number	e90
Journal	Blood Cancer Journal
Volume	2
Issue number	9
DOIs	https://doi.org/10.1038/bcj.2012.32
State	Published - Sep 2012
Externally published	Yes

Keywords

AL amyloidosis
cancer-testis antigens
stem cell transplantation

Access to Document

10.1038/bcj.2012.32

Cite this

@article{3860fa7b362b41eb875adb6d27e4de72,

title = "Cancer-testis antigen expression and immunogenicity in AL amyloidosis",

abstract = "Light-chain amyloidosis (AL) is a plasma cell dyscrasia closely related to multiple myeloma. In multiple myeloma, the cancer-testis antigens (CTAs) CT7 (MAGE-C1), CT10 (MAGE-C2) and MAGE-A CTAs are expressed in up to 80\% of cases. In this study, we investigated the expression and immunogenicity of several CTAs in patients with AL amyloidosis in a total of 38 bone marrow specimens by employing standard immunohistochemistry techniques on paraffin-embedded archival tissues. Plasma samples from 35 patients (27 with matched bone marrow samples) were also analyzed by ELISA for sero reactivity to a group of full-length CTA proteins. CT7 was present in 25/38 (66\%) while CT10 was demonstrated in 3/38 and GAGE in 1/38 AL amyloid cases. The expression pattern was mostly focal. There were no significant differences with regard to organ involvement, response to treatment, or prognosis in CTA positive compared to negative cases. None of the specimens showed spontaneous humoral immunity to CT7, but sero reactivity was observed in individual patients to other CTAs. This study identifies CT7 as the prevalent CTA in plasma cells of patients with AL amyloidosis. Further analyses determining the biology of CTAs in AL amyloidosis and their value as potential targets for immunotherapy are warranted.",

keywords = "AL amyloidosis, cancer-testis antigens, stem cell transplantation",

author = "Rosenzweig, \{M. A.\} and H. Landau and D. Seldin and C. Ohara and S. Girnius and N. Hanson and D. Frosina and C. Sedrak and M. Arcila and Comenzo, \{R. L.\} and S. Giralt and S. Gnjatic and Jungbluth, \{A. A.\} and G. Koehne",

note = "Funding Information: This work was supported by a grant from Empire Clinical Research Investigator Program (ECRIP) and partially by the Cancer Research Institute.",

year = "2012",

month = sep,

doi = "10.1038/bcj.2012.32",

language = "English",

volume = "2",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Cancer-testis antigen expression and immunogenicity in AL amyloidosis

AU - Rosenzweig, M. A.

AU - Landau, H.

AU - Seldin, D.

AU - Ohara, C.

AU - Girnius, S.

AU - Hanson, N.

AU - Frosina, D.

AU - Sedrak, C.

AU - Arcila, M.

AU - Comenzo, R. L.

AU - Giralt, S.

AU - Gnjatic, S.

AU - Jungbluth, A. A.

AU - Koehne, G.

N1 - Funding Information: This work was supported by a grant from Empire Clinical Research Investigator Program (ECRIP) and partially by the Cancer Research Institute.

PY - 2012/9

Y1 - 2012/9

N2 - Light-chain amyloidosis (AL) is a plasma cell dyscrasia closely related to multiple myeloma. In multiple myeloma, the cancer-testis antigens (CTAs) CT7 (MAGE-C1), CT10 (MAGE-C2) and MAGE-A CTAs are expressed in up to 80% of cases. In this study, we investigated the expression and immunogenicity of several CTAs in patients with AL amyloidosis in a total of 38 bone marrow specimens by employing standard immunohistochemistry techniques on paraffin-embedded archival tissues. Plasma samples from 35 patients (27 with matched bone marrow samples) were also analyzed by ELISA for sero reactivity to a group of full-length CTA proteins. CT7 was present in 25/38 (66%) while CT10 was demonstrated in 3/38 and GAGE in 1/38 AL amyloid cases. The expression pattern was mostly focal. There were no significant differences with regard to organ involvement, response to treatment, or prognosis in CTA positive compared to negative cases. None of the specimens showed spontaneous humoral immunity to CT7, but sero reactivity was observed in individual patients to other CTAs. This study identifies CT7 as the prevalent CTA in plasma cells of patients with AL amyloidosis. Further analyses determining the biology of CTAs in AL amyloidosis and their value as potential targets for immunotherapy are warranted.

AB - Light-chain amyloidosis (AL) is a plasma cell dyscrasia closely related to multiple myeloma. In multiple myeloma, the cancer-testis antigens (CTAs) CT7 (MAGE-C1), CT10 (MAGE-C2) and MAGE-A CTAs are expressed in up to 80% of cases. In this study, we investigated the expression and immunogenicity of several CTAs in patients with AL amyloidosis in a total of 38 bone marrow specimens by employing standard immunohistochemistry techniques on paraffin-embedded archival tissues. Plasma samples from 35 patients (27 with matched bone marrow samples) were also analyzed by ELISA for sero reactivity to a group of full-length CTA proteins. CT7 was present in 25/38 (66%) while CT10 was demonstrated in 3/38 and GAGE in 1/38 AL amyloid cases. The expression pattern was mostly focal. There were no significant differences with regard to organ involvement, response to treatment, or prognosis in CTA positive compared to negative cases. None of the specimens showed spontaneous humoral immunity to CT7, but sero reactivity was observed in individual patients to other CTAs. This study identifies CT7 as the prevalent CTA in plasma cells of patients with AL amyloidosis. Further analyses determining the biology of CTAs in AL amyloidosis and their value as potential targets for immunotherapy are warranted.

KW - AL amyloidosis

KW - cancer-testis antigens

KW - stem cell transplantation

UR - https://www.scopus.com/pages/publications/84871035125

U2 - 10.1038/bcj.2012.32

DO - 10.1038/bcj.2012.32

M3 - Article

AN - SCOPUS:84871035125

SN - 2044-5385

VL - 2

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 9

M1 - e90

ER -

Cancer-testis antigen expression and immunogenicity in AL amyloidosis

Abstract

Keywords

Access to Document

Fingerprint

Cite this